Lexicon Pharmaceuticals

$1.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-4.41%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell LXRX and other stocks, options, ETFs, and crypto commission-free!

About LXRX

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. Read More The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Employees
202
Headquarters
The Woodlands, Texas
Founded
1995
Market Cap
144.53M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.18M
High Today
$1.37
Low Today
$1.30
Open Price
$1.36
Volume
859.90K
52 Week High
$11.88
52 Week Low
$1.13

Collections

LXRX News

ReutersAug 3

Edited Transcript of LXRX earnings conference call or presentation 31-Jul-19 12:00pm GMT

456
BenzingaJul 29

Lexicon Pharmaceuticals, Inc. - What Caused The Opening Gap In Lexicon?

8,161
BenzingaJul 29

Lexicon Pharmaceuticals, Inc., Sanofi - Lexicon Shares Fall 47% On Termination Of License Agreement With Sanofi

6,360

LXRX Earnings

-$0.43
-$0.31
-$0.20
-$0.08
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Oct 31, Pre-Market

More LXRX News

MarketWatchJul 26

Lexicon stock tanks after Sanofi ends partnership

1,316
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.